NCT03025256 - Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 2, 2018

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions

Acral Lentiginous MelanomaCentral Nervous System MelanomaClinical Stage IV Cutaneous Melanoma AJCC v8Leptomeningeal NeoplasmMelanocytomaMetastatic Lung Non-Small Cell CarcinomaMetastatic MelanomaMetastatic Mucosal MelanomaMetastatic Uveal MelanomaStage IV Lung Cancer AJCC v8

Interventions

PROCEDURE

Biospecimen Collection

Correlative studies

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Lumbar Puncture

Undergo lumbar puncture for cerebrospinal fluid collection

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI of brain and spine

BIOLOGICAL

Nivolumab

Given IV or IT

PROCEDURE

Positron Emission Tomography

Undergo PET

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER